Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and dissemina...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Papp-Wallace, Krisztina M., Bethel, Christopher R., Caillon, Jocelyne, Barnes, Melissa D., Potel, Gilles, Bajaksouzian, Saralee, Rutter, Joseph D., Reghal, Amokrane, Shapiro, Stuart, Taracila, Magdalena A., Jacobs, Michael R., Bonomo, Robert A., Jacqueline, Cédric
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2019
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496078/
https://ncbi.nlm.nih.gov/pubmed/30858223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00105-19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires